The stock of SeaSpine Holdings Corp (NASDAQ:SPNE) hit a new 52-week low and has $6.46 target or 8.00% below today’s $7.02 share price. The 6 months bearish chart indicates high risk for the $79.34M company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $6.46 price target is reached, the company will be worth $6.35M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 58,864 shares traded hands or 68.64% up from the average. SeaSpine Holdings Corp (NASDAQ:SPNE) has declined 51.44% since April 21, 2016 and is downtrending. It has underperformed by 56.77% the S&P500.
Analysts await SeaSpine Holdings Corp (NASDAQ:SPNE) to report earnings on March, 21. They expect $-0.36 earnings per share, up 70.73% or $0.87 from last year’s $-1.23 per share. After $-0.84 actual earnings per share reported by SeaSpine Holdings Corp for the previous quarter, Wall Street now forecasts -57.14% EPS growth.
According to Zacks Investment Research, “SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California.”
More news for SeaSpine Holdings Corp (NASDAQ:SPNE) were recently published by: Quotes.Wsj.com, which released: “News SeaSpine Holdings Corp.SPNE” on June 27, 2015. Streetinsider.com‘s article titled: “Form 4 SeaSpine Holdings Corp For: Nov 18 Filed by: Valentine Keith” and published on November 21, 2016 is yet another important article.
SPNE Company Profile
SeaSpine Holdings Corporation, incorporated on February 12, 2015, is a medical technology company. The Firm is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Firm operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment. The Firm has a portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.